136 related articles for article (PubMed ID: 19173990)
1. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
[TBL] [Abstract][Full Text] [Related]
2. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
3. [Expressions of VEGF/VEGFRs and activation of STATs in ovarian carcinoma].
Chen BY; Ye DF; Xie X; Chen HZ; Lü WG
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):33-7. PubMed ID: 15771796
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
Brustmann H; Naudé S
Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
[TBL] [Abstract][Full Text] [Related]
5. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX
Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
[TBL] [Abstract][Full Text] [Related]
7. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
8. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
9. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
10. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
[TBL] [Abstract][Full Text] [Related]
11. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
13. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
Shao SL; Cai Y; Wang QH; Yan LJ; Zhao XY; Wang LX
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
[TBL] [Abstract][Full Text] [Related]
14. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma.
Wang X; Wei Z; Gao F; Zhang X; Zhou C; Zhu F; Wang Q; Gao Q; Ma C; Sun W; Kong B; Zhang L
Anticancer Res; 2008; 28(5B):2991-6. PubMed ID: 19031945
[TBL] [Abstract][Full Text] [Related]
19. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
20. [Expression of THY1 gene in epithelial ovarian cancer].
Zeng LQ; Peng ZL; Duan ZL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):118-20. PubMed ID: 19538887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
